<DOC>
	<DOCNO>NCT00184574</DOCNO>
	<brief_summary>This trial conduct Europe . This trial aim comparison effect glycemic control subject type 2 diabetes three different premixed insulin analogue give combination oral anti-diabetic drug .</brief_summary>
	<brief_title>Comparison Biphasic Insulin Aspart 70/30 , 50/50 , 30/70 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Currently treat insulin Currently treat Metformin HbA1c : 7.512.0 % Body Mass Index ( BMI ) &lt; 25.0 &gt; 40.0 kg/m2 Metformin contraindication accord local practice TZDs within 6 month prior randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>